LeMaitre Vascular, Inc. (LMAT) To Go Ex-Dividend on March 13th

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced a quarterly dividend on Tuesday, February 18th, Wall Street Journal reports. Shareholders of record on Thursday, March 13th will be paid a dividend of 0.20 per share by the medical instruments supplier on Thursday, March 27th. This represents a $0.80 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date is Thursday, March 13th. This is a 25.0% increase from LeMaitre Vascular’s previous quarterly dividend of $0.16.

LeMaitre Vascular has increased its dividend payment by an average of 13.3% annually over the last three years and has increased its dividend every year for the last 14 years. LeMaitre Vascular has a payout ratio of 32.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect LeMaitre Vascular to earn $2.17 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 36.9%.

LeMaitre Vascular Trading Up 0.6 %

Shares of NASDAQ:LMAT opened at $81.88 on Tuesday. LeMaitre Vascular has a 12 month low of $62.39 and a 12 month high of $109.58. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 44.74, a PEG ratio of 2.22 and a beta of 0.89. The firm’s 50-day moving average is $96.07 and its 200 day moving average is $94.92.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $55.81 million for the quarter, compared to analysts’ expectations of $55.99 million. As a group, equities analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on LMAT shares. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective for the company. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital raised their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.